G W Witherell

Summary

Publications

  1. ncbi Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response
    G W Witherell
    RiboGene Inc, Hayward, California, USA
    J Med Virol 63:8-16. 2001
  2. ncbi AG-7088 Pfizer
    G Witherell
    Questcor Pharmaceuticals Inc, 26118 Research Road, Hayward, CA 94545, USA
    Curr Opin Investig Drugs 1:297-302. 2000
  3. ncbi BMS-232632 (Novartis/Bristol-Myers Squibb)
    G Witherell
    Questcor Pharmaceuticals Inc, Hayward, CA 94545, USA
    Curr Opin Investig Drugs 2:340-7. 2001
  4. ncbi ISIS-14803 (Isis Pharmaceuticals)
    G W Witherell
    Questor Pharmaceuticals Inc, Union City, CA 94587, USA
    Curr Opin Investig Drugs 2:1523-9. 2001
  5. ncbi XTL-001. XTL Pharmaceuticals
    Gary Witherell
    Questcor Pharmaceuticals Inc, Union City, CA 94587 1217, USA
    Curr Opin Investig Drugs 3:684-92. 2002
  6. ncbi Oral typhoid vaccine. Acambis/Berna
    Gary W Witherell
    Questcor Pharmaceuticals Inc, 3260 Whipple Road, Union City, CA 94587 1217, USA
    Curr Opin Investig Drugs 4:1010-8. 2003
  7. ncbi Glyminox Biosyn
    Gary W Witherell
    Questor Pharmaceuticals Inc, 3260 Whipple Road, Union City, CA 94587, USA
    Curr Opin Investig Drugs 5:222-31. 2004

Detail Information

Publications7

  1. ncbi Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response
    G W Witherell
    RiboGene Inc, Hayward, California, USA
    J Med Virol 63:8-16. 2001
    ..Substitutions that are most likely to be tolerated or detrimental to NS5A function in the IFN-response mechanism were identified as a first step toward site directed mutagenesis of the ISDR...
  2. ncbi AG-7088 Pfizer
    G Witherell
    Questcor Pharmaceuticals Inc, 26118 Research Road, Hayward, CA 94545, USA
    Curr Opin Investig Drugs 1:297-302. 2000
    ..Of this series, AG-7088 was the most potent inhibitor [324635]. In May 2000, Merrill Lynch predicted that phase III trials would begin in the first half of 2000 and that US filing would take place in the second half of 2001 [375962]...
  3. ncbi BMS-232632 (Novartis/Bristol-Myers Squibb)
    G Witherell
    Questcor Pharmaceuticals Inc, Hayward, CA 94545, USA
    Curr Opin Investig Drugs 2:340-7. 2001
    ..The analysts predicted peak sales would occur in 2007, with sales of $500 million in the US and $300 million in the rest of the world at that time [319225]...
  4. ncbi ISIS-14803 (Isis Pharmaceuticals)
    G W Witherell
    Questor Pharmaceuticals Inc, Union City, CA 94587, USA
    Curr Opin Investig Drugs 2:1523-9. 2001
    ..In October 2001, Isis reported that it had earned a $1.5 million research milestone payment from Merck for progress in this collaboration [426015]...
  5. ncbi XTL-001. XTL Pharmaceuticals
    Gary Witherell
    Questcor Pharmaceuticals Inc, Union City, CA 94587 1217, USA
    Curr Opin Investig Drugs 3:684-92. 2002
    ..XTL has anticipated that XTL-001 will be used as a combination therapy with existing drugs. In March 2002, Roberton Stephens predicted a 2006 launch for XTL-001, with sales expected to reach at least US$100 million...
  6. ncbi Oral typhoid vaccine. Acambis/Berna
    Gary W Witherell
    Questcor Pharmaceuticals Inc, 3260 Whipple Road, Union City, CA 94587 1217, USA
    Curr Opin Investig Drugs 4:1010-8. 2003
    ....
  7. ncbi Glyminox Biosyn
    Gary W Witherell
    Questor Pharmaceuticals Inc, 3260 Whipple Road, Union City, CA 94587, USA
    Curr Opin Investig Drugs 5:222-31. 2004
    ..In March 2002, glyminox was in phase II/III trials for Chlamydia treatment and as a contraceptive, and in phase II trials for herpes simplex virus shedding...